PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services.
PAION’s mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare.
PAION's Strategy & Partnering
Teleconference & webcast
31 March 2021
PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY...
DGAP-News: PAION AG / Key word(s): Product Launch 16.07.2021 /...
PAION ANNOUNCES THAT NMPA ACCEPTS SUBMISSION OF NEW DRUG APPLICATION FOR...
DGAP-News: PAION AG / Key word(s): Regulatory Admission...
PAION RECEIVES UK MHRA APPROVAL OF BYFAVO (REMIMAZOLAM) FOR PROCEDURAL SEDATION
DGAP-News: PAION AG / Key word(s): Regulatory Approval 29.06.2021...
I consent to the display of external content. This enables personal data to be transmitted to third-party platforms. Read more about our